|
Malignant neoplasm of prostate
|
0.350 |
Biomarker
|
disease |
CTD_human |
CD276 and the alternative checkpoint inhibition PVR/NECTIN2/CD226/TIGIT pathway emerged as relevant to PC checkpoint inhibition target development.
|
30614027 |
2019 |
|
Malignant neoplasm of prostate
|
0.350 |
Biomarker
|
disease |
BEFREE |
B7-H3 in tissue samples was significantly higher in the prostate cancer group than in the benign prostatic hyperplasia group (mean±SEM 174.73±56.80 vs 82.69±46.19 ng/gm, p<0.001).
|
21784485 |
2011 |
|
Malignant neoplasm of prostate
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
Here we used genomic expression data to examine the relationship between B7-H3 mRNA expression and prostate cancer.
|
27801901 |
2017 |
|
Malignant neoplasm of prostate
|
0.350 |
Biomarker
|
disease |
BEFREE |
In conclusion, blocking mtDNA replication by EtBr induces increased expression of stemness genes, such as Oct3/4, Nanog, CD44, and ABCG2, in addition to the immune regulator B7-H3 in PC-3 and DU145 prostate cancer cell lines.
|
23634795 |
2013 |
|
Malignant neoplasm of prostate
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of coinhibitory B7x and B7-H3 in prostate cancer correlates with poor disease outcome, whereas tumor-infiltrating immune cells have enhanced expression of PD-L1 and its receptor PD-1.
|
20971039 |
2011 |
|
Malignant neoplasm of prostate
|
0.350 |
Biomarker
|
disease |
BEFREE |
CD276 and the alternative checkpoint inhibition PVR/NECTIN2/CD226/TIGIT pathway emerged as relevant to PC checkpoint inhibition target development.
|
30614027 |
2019 |
|
Liver carcinoma
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
In this study, we investigated the expression of B7-H3 in tissues and cells of primary hepatocellular carcinoma (PHC) patients.
|
24787022 |
2014 |
|
Liver carcinoma
|
0.350 |
Biomarker
|
disease |
BEFREE |
Large subcutaneous H22 HCCs (0.7-0.8 cm in diameter) established in BALB/c mice were rapidly and completely eradicated when intratumoral administration of As(2)O(3) was preceded by in situ gene transfer of B7H3.
|
16217749 |
2006 |
|
Liver carcinoma
|
0.350 |
Therapeutic
|
disease |
CTD_human |
Large subcutaneous H22 HCCs (0.7-0.8 cm in diameter) established in BALB/c mice were rapidly and completely eradicated when intratumoral administration of As(2)O(3) was preceded by in situ gene transfer of B7H3.
|
16217749 |
2006 |
|
Liver carcinoma
|
0.350 |
Biomarker
|
disease |
BEFREE |
Taken together, these results indicated that B7‑H2‑ and/or B7‑H3‑positive expression indicates a poor clinical outcome for patients, and the combination of B7‑H2 and B7‑H3 may be a preferential prognostic biomarker in patients with HCC.
|
30942404 |
2019 |
|
Liver carcinoma
|
0.350 |
Biomarker
|
disease |
BEFREE |
Early Detection of Hepatocellular Carcinoma in Patients with Hepatocirrhosis by Soluble B7-H3.
|
28243980 |
2017 |
|
Liver carcinoma
|
0.350 |
Biomarker
|
disease |
BEFREE |
Involvement of soluble B7-H3 in combination with the serum inflammatory cytokines interleukin-17, -8 and -6 in the diagnosis of hepatocellular carcinoma.
|
29344257 |
2017 |
|
Liver Cirrhosis, Experimental
|
0.300 |
Biomarker
|
disease |
CTD_human |
Systems level analysis and identification of pathways and networks associated with liver fibrosis.
|
25380136 |
2014 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study reports novel functions of B7-H3 in regulating breast cancer stem cell enrichment.
|
30082909 |
2019 |
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Therefore, a method with high resolution and specificity for intraoperative margin assessment is needed.<b>Experimental Design:</b> First, quantitative immunofluorescence staining of B7-H3 expression was assessed in four pathologic stages of breast cancer progression of the MMTV-PyMT transgenic murine model.
|
29712688 |
2018 |
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Blood from 50 patients suffering from breast cancer was analyzed for CETCs and the expression of B7-H3 and Ki-67 using the maintrac® method.
|
30226585 |
2018 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
MicroRNAs targeting B7-H3 were identified by transfecting two breast cancer cell lines with a library of 810 miRNA mimics and quantifying changes of B7-H3 protein levels using protein lysate microarrays.
|
24577056 |
2014 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
We observed that silencing of B7-H3, via stable short hairpin RNA or transient short interfering RNA transfection, increased the sensitivity of multiple human breast cancer cell lines to paclitaxel as a result of enhanced drug-induced apoptosis.
|
21518725 |
2011 |
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In particular, B7-H3 (CD276), a cellular receptor expressed in breast cancer, was imaged via sPA and fluorescence molecular imaging to differentiate invasive tumors from normal glands in mice.
|
31082216 |
2019 |
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The tumor promoter phorbol 12-myristate 13-acetate (PMA) enhanced the expression of 4Ig-hB7H3 in FEMX-I (melanoma), MA11 (breast cancer), and OHS (osteosarcoma) cells, suggesting that 4Ig-hB7H3 may be implicated in tumorigenesis.
|
18690846 |
2008 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Conclusions:</b> B7-H3 is a promising target for both vascular and epithelial sPA imaging of breast cancer.
|
28529630 |
2017 |
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Quantitative PCR results showed that the expression levels of CD24 and B7-H3 mRNA in breast cancer tissues were significantly higher than those in adjacent tissues (P<0.05).
|
29344150 |
2017 |
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Decreased expression of B7-H3 reduces the glycolytic capacity and sensitizes breast cancer cells to AKT/mTOR inhibitors.
|
26771843 |
2016 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, we showed that B7-H3 increased glucose consumption and lactate production by promoting hexokinase 2 (HK2) expression in CRC cells, and we also found that HK2 was a key mediator of B7-H3-induced CRC chemoresistance.
|
30952834 |
2019 |
|
Colorectal Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In CRC cell lines with stable expression of high B7-H3, the mRNA and protein expressions of B3GALT4 were significantly upregulated.
|
30131660 |
2018 |